Top 10 similar words or synonyms for xalatan

travatan    0.867341

lumigan    0.857523

cosopt    0.847214

trusopt    0.841624

xalacom    0.837851

azopt    0.829200

rescula    0.819393

pilocar    0.805490

timoptic    0.796546

combigan    0.793517

Top 30 analogous words or synonyms for xalatan

Article Example
Latanoprost The brand Xalatan is manufactured by Pfizer and had annual sales of approximately $1.6 billion.
László Z. Bitó In the United States László Bitó has built an academic career as an internationally known professor of physiology. Most of his academic career is connected to Columbia University (where he is Professor Emeritus of Ocular Physiology) and to the University of Puerto Rico where he studied the effect of ageing on the eyes of monkeys. The fruit of his research is Xalatan, the medicine for glaucoma. The development of Xalatan brought a fundamental change to the treatment of this blinding disease. He published more than 140 scientific papers and was awarded with the Proctor Medal (2000) and Columbia University Award for Distinguished Achievement (2004).
Latanoprost Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye. This includes ocular hypertension and open angle glaucoma. It is applied as eye drops to the eyes. Onset of effects is usually within four hours, and they last for up to a day.
Trabecular meshwork The trabecular meshwork is assisted to a small degree in the drainage of aqueous humour by a second outflow pathway, the uveo-scleral pathway (5-10% of outflow occurs this way). The uveo-scleral pathway is increased with the use of glaucoma drugs such as prostaglandins (e.g., Xalatan, Travatan).
Carl B. Camras Carl B. Camras (November 23, 1953 – April 14, 2009) was an American ophthalmologist known for his research on the treatment of glaucoma. He discovered a new class of drugs to treat glaucoma—prostaglandin analogues. Specifically, he developed latanoprost sold under the trade name Xalatan, which is the most widely used glaucoma medication.
Bayh–Dole Act In "In the Case of Xalatan" the NIH received a request from Essential Inventions in January 2004 to adopt a policy of granting march-in licenses to patents when the patent owner charged significantly higher prices in the United States than they did in other high income countries, on the basis of Pfizer's glaucoma drug being sold in the United States at two to five times the prices in other high income countries. The NIH held that "the extraordinary remedy of march-in was not an appropriate means for controlling prices."
Columbia University Columbia scientists have been credited with about 175 new inventions in the health sciences each year. More than 30 pharmaceutical products based on discoveries and inventions made at Columbia are on the market today. These include Remicade (for arthritis), Reopro (for blood clot complications), Xalatan (for glaucoma), Benefix, Latanoprost (a glaucoma treatment), shoulder prosthesis, homocysteine (testing for cardiovascular disease), and Zolinza (for cancer therapy). Columbia Technology Ventures (formerly Science and Technology Ventures), , manages some 600 patents and more than 250 active license agreements. Patent-related deals earned Columbia more than $230 million in the 2006 fiscal year, according to the university, more than any university in the world.
Sturge–Weber syndrome Latanoprost (Xalatan), a prostaglandin, may significantly reduce IOP (intraocular pressure) in patients with glaucoma associated with Sturge–Weber syndrome. Latanoprost is commercially formulated as an aqueous solution in a concentration of 0.005% preserved with 0.02% benzalkonium chloride (BAC). The recommended dosage of latanoprost is one drop daily in the evening, which permits better diurnal IOP control than does morning instillation. Its effect is independent of race, gender or age, and it has few to no side effects. Contraindications include a history of CME, epiretinal membrane formation, vitreous loss during cataract surgery, history of macular edema associated with branch retinal vein occlusion, history of anterior uveitis, and diabetes mellitus. It is also wise to advise patients that unilateral treatment can result in heterochromia or hypertrichosis that may become cosmetically objectionable.
Fight for Sight (U.S.) Numerous leaders in eye and vision research and academia received a Fight for Sight grant early in their careers, including Harold Scheie, MD (1950), who founded the Scheie Eye Institute at the University of Pennsylvania, Arthur Jampolsky, MD (1952), whose efforts led to the creation of the Smith-Kettlewell Eye Research Institute, A. Edward Maumenee, MD (1958) director of the Wilmer Eye Institute, founder of the Eye Bank Association of America and potent force behind the creation of the NEI at the National Institutes of Health, Carl Kupfer, MD (1961), Director of the NEI for 30 years, László Bitó, PhD (1965), who developed the glaucoma drug Xalatan, Robert Machemer, MD (1966) the “father” of modern retinal surgery, Irene H. Maumenee, MD (1973) internationally renowned pediatric ophthalmologist and expert in hereditary eye diseases, David Abramson, MD (1979), renowned for his expertise in treating childhood eye tumors, Paul Sieving, MD, PhD (1980), current Director of the NEI and Jayakrishna Ambati, MD (2002), winner of the ARVO Cogan Award, given for significant scientific accomplishments to a scientist under 40 years old.
László Z. Bitó László Bitó was born in Budapest, Hungary. His family was forced to leave Budapest during the Communist era. He served in a mine in Komló and became a local leader of the revolution in 1956. After the revolution was crushed by Russian forces, he fled to the United States where he won a scholarship and became a physiologist. He was granted asylum in the United States and came to Bard College in the winter field period of 1956–57. Bitó graduated from Bard College in 1960 as a pre-med biology major. He went on to obtain his Ph.D. from Columbia University in medical cell biology in 1963. His research led to the development of Xalatan, the drug that has saved the sight of millions of glaucoma sufferers. He has published more than 150 scientific articles and received, among many other honors, the highest recognition in the field of eye research, the Proctor Medal, in 2000 and the Helen Keller Prize for Vision Research in 2013. Upon retiring from Columbia University as Emeritus Professor of Ocular Physiology, he returned to Hungary and his first love of writing. Of his 14 nonscientific books—novels, essays, and three anthologies of some of his more than a hundred newspaper and magazine articles—some have appeared in translations in half a dozen countries.